Natural Alternatives Intl (NAII) Posts Robust Profit Growth; FDA’s Decision Boosts TherapeuticsMD (TXMD)

natural_alternatives_international_naii

Natural Alternatives International, Inc. (Nasdaq:NAII) shares soared more than 17% in the extended session Monday after the company delivered significant financial growth in its quarterly report

For its fourth quarter fiscal 2016, Natural Alternatives posted net sales of $35.7 million, a 58.1% increase year over year, and net income of $3.4 million, or $0.52 per diluted share versus net income of $1.0 million, or $0.15 per diluted share in the same period the prior year

NAII stock closed at $10.16, up $0.24 (or +2.42%) and 11,081 of its shares changed hands during the day

Natural Alternatives International, which engages in formulating, manufacturing, and marketing nutritional supplements, has 6.87M Shares Outstanding and NAII stock one-year range is between $5.40 and $14.50. At close on Monday, the company had a Market Capitalization of $69.79M

*

http://galaxystocks.com/wp-content/uploads/2015/12/TherapeuticsMD_TXMD-300x35.png

Shares of TherapeuticsMD, Inc. (NYSEMKT:TXMD) surged over 6% in after-hours trading Monday as the company said that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for its investigational dyspareunia treatment Yuvvexy.

TXMD stock finished the regular session in negative territory by 1.19% (or -$0.08) at $6.67 with a total volume of 1.67M shares traded

TherapeuticsMD, an innovative women’s healthcare company, has 196.49M Shares Outstanding, Market Capitalization (intraday) of $1.31B and TXMD stock 52-week range is from $5.18 to $11.26 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/